ISM7594 / Insilico Medicine - LARVOL DELTA

JMC | Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors (Insilico Medicine Press Release) - "This research, recently published in the Journal of Medicinal Chemistry, provides an innovative approach for the discovery and development of next-generation cancer therapies targeting FGFR2/3....In the validation studies, ISM7594 exhibits nanomolar inhibitory activity against FGFR2 and FGFR3, with over 100-fold selectivity relative to FGFR1/4. It maintained strong efficacy against clinically relevant FGFR2/3 mutants associated with therapeutic resistance. In cancer cell lines harboring FGFR2/3 alterations, ISM7594 showed robust antiproliferative effects, while exhibiting minimal impact on cells without FGFR aberrations. In preclinical animal models, ISM7594 displayed favorable pharmacokinetic properties, significant tumor growth inhibition, and a reduced toxicity profile compared to less selective FGFR inhibitors."

New molecule • Preclinical • Oncology